Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Cephalalgia

Retrieve available abstracts of 187 articles:
HTML format

Single Articles

    November 2022
  1. SAMPATAKAKIS SN, Lymperopoulos L, Mavridis T, Karagiorgis G, et al
    Visual snow: A systematic review and a case series.
    Cephalalgia. 2022;42:1409-1419.
    PubMed     Abstract available

  2. CITAK A, Kilinc E, Torun IE, Ankarali S, et al
    The effects of certain TRP channels and voltage-gated KCNQ/Kv7 channel opener retigabine on calcitonin gene-related peptide release in the trigeminovascular system.
    Cephalalgia. 2022;42:1375-1386.
    PubMed     Abstract available

  3. BASEDAU H, Oppermann T, Gundelwein Silva E, Peng KP, et al
    Galcanezumab modulates Capsaicin-induced C-fiber reactivity.
    Cephalalgia. 2022;42:1331-1338.
    PubMed     Abstract available

    October 2022
  4. MARTINS-OLIVEIRA M, Akerman S, Holland PR, Tavares I, et al
    Pharmacological modulation of ventral tegmental area neurons elicits changes in trigeminovascular sensory processing and is accompanied by glycemic changes: Implications for migraine.
    Cephalalgia. 2022 Oct 18:3331024221110111. doi: 10.1177/03331024221110111.
    PubMed     Abstract available

  5. RIESENBERG R, Gaul C, Stroud CE, Dong Y, et al
    Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache.
    Cephalalgia. 2022;42.
    PubMed     Abstract available

  6. EVERS S, Holle-Lee D, Schankin CJ, Kull P, et al
    Visual snow syndrome is probably not mediated by CGRP: A case series.
    Cephalalgia. 2022;42.
    PubMed     Abstract available

  7. LANGER LK, Bayley MT, Lawrence DW, Comper P, et al
    Revisiting the ICHD-3 criteria for headache attributed to mild traumatic injury to the head: Insights from the Toronto Concussion Study Analysis of Acute Headaches Following Concussion.
    Cephalalgia. 2022;42.
    PubMed     Abstract available

  8. RAY JC, Pham X, Foster E, Cheema S, et al
    The prevalence of headache disorders in Postural Tachycardia Syndrome: A systematic review and meta-analysis of the literature.
    Cephalalgia. 2022;42.
    PubMed     Abstract available

    September 2022
  9. LANTERI-MINET M, Ducros A, Francois C, Olewinska E, et al
    Effectiveness of onabotulinumtoxinA (BOTOX(R)) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data.
    Cephalalgia. 2022 Sep 8:3331024221123058. doi: 10.1177/03331024221123058.
    PubMed     Abstract available

  10. TSAO YC, Wang YF, Fuh JL, Chen WT, et al
    Non-aura visual disturbance with high visual aura rating scale scores has stronger association with migraine chronification than typical aura.
    Cephalalgia. 2022 Sep 6:3331024221123074. doi: 10.1177/03331024221123074.
    PubMed     Abstract available

  11. KELLIER DJ, Marquez de Prado B, Haagen D, Grabner P, et al
    Development of a text message-based headache diary in adolescents and children.
    Cephalalgia. 2022;42:1013-1021.
    PubMed     Abstract available

    August 2022
  12. MACGREGOR EA, Komori M, Krege JH, Baygani S, et al
    Efficacy of lasmiditan for the acute treatment of perimenstrual migraine.
    Cephalalgia. 2022 Aug 18:3331024221118929. doi: 10.1177/03331024221118929.
    PubMed     Abstract available

  13. THURAIAIYAH J, Erritzoe-Jervild M, Al-Khazali HM, Schytz HW, et al
    The role of cytokines in migraine: A systematic review.
    Cephalalgia. 2022 Aug 12:3331024221118924. doi: 10.1177/03331024221118924.
    PubMed     Abstract available

  14. HENDRIKSE ER, Rees TA, Tasma Z, Le Foll C, et al
    Calcitonin receptor antibody validation and expression in the rodent brain.
    Cephalalgia. 2022;42:815-826.
    PubMed     Abstract available

  15. STRASSMAN AM, Melo-Carrillo A, Houle TT, Adams A, et al
    Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.
    Cephalalgia. 2022;42:933-943.
    PubMed     Abstract available

  16. THUNSTEDT DC, Schmutzer M, Fabritius MP, Thorsteinsdottir J, et al
    Headache characteristics and postoperative course in Chiari I malformation.
    Cephalalgia. 2022;42:879-887.
    PubMed     Abstract available

    July 2022
  17. IKUMI N, Cerda-Company X, Marti-Marca A, Vila-Ballo A, et al
    Avoidance behaviour modulates but does not condition phonophobia in migraine.
    Cephalalgia. 2022 Jul 9:3331024221111772. doi: 10.1177/03331024221111772.
    PubMed     Abstract available

  18. OLESEN J
    Personal view: Modelling pain mechanisms of migraine without aura.
    Cephalalgia. 2022 Jul 7:3331024221111529. doi: 10.1177/03331024221111529.
    PubMed     Abstract available

  19. STEINER TJ, Terwindt GM, Katsarava Z, Pozo-Rosich P, et al
    Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process.
    Cephalalgia. 2022 Jul 5:3331024221110102. doi: 10.1177/03331024221110102.
    PubMed     Abstract available

  20. VIGANO A, Toscano M, Petolicchio B, Bianchi A, et al
    Letter to the editor regarding "Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial".
    Cephalalgia. 2022 Jul 3:3331024221111528. doi: 10.1177/03331024221111528.

  21. BRANDT RB, Cnossen VM, Doesborg PG, Coo IF, et al
    Unilateral increased visual sensitivity in cluster headache: a cross-sectional study.
    Cephalalgia. 2022;42:722-729.
    PubMed     Abstract available

  22. ZHOU Y, Zhang F, Starcevic Manning M, Hu Z, et al
    Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions.
    Cephalalgia. 2022;42:749-760.
    PubMed     Abstract available

  23. IANNONE LF, De Cesaris F, Ferrari A, Benemei S, et al
    Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine.
    Cephalalgia. 2022 Jul 1:3331024221111526. doi: 10.1177/03331024221111526.
    PubMed     Abstract available

    June 2022
  24. MAKAREVICIUS G, Ryliskiene K
    Successful treatment of primary headache associated with sexual activity using erenumab: Case report.
    Cephalalgia. 2022;42:680-683.
    PubMed     Abstract available

  25. OLIVEIRA R, Placido M, Pereira L, Machado S, et al
    Headaches and the use of personal protective equipment in the general population during the COVID-19 pandemic.
    Cephalalgia. 2022;42:608-617.
    PubMed     Abstract available

  26. PENSATO U, Baraldi C, Favoni V, Mascarella D, et al
    Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.
    Cephalalgia. 2022;42:645-653.
    PubMed     Abstract available

  27. RAIBIN K, Markus TE
    Cutaneous allodynia in pediatric and adolescent patients and their mothers: A comparative study.
    Cephalalgia. 2022;42:579-589.
    PubMed     Abstract available

    May 2022
  28. SUDAT SE, Jacobson AS, Avins AL, Lipton RB, et al
    A population-health approach to characterizing migraine by comorbidity: Results from the Mindfulness and Migraine Cohort Study.
    Cephalalgia. 2022 May 31:3331024221104180. doi: 10.1177/03331024221104180.
    PubMed     Abstract available

  29. CHRISTENSEN CG, Techlo TR, Kogelman LJ, Wegner Thorner L, et al
    Population-based prevalence of cranial autonomic symptoms in migraine and proposed diagnostic appendix criteria.
    Cephalalgia. 2022 May 29:3331024221094548. doi: 10.1177/03331024221094548.
    PubMed     Abstract available

  30. EVERS S, Frese A, Summ O, Husstedt IW, et al
    Levetiracetam in the prophylactic treatment of episodic migraine: A prospective open label study.
    Cephalalgia. 2022 May 27:3331024221103815. doi: 10.1177/03331024221103815.
    PubMed     Abstract available

  31. MOUAANAKI SA, Carlsen LN, Bendtsen L, Jensen RH, et al
    Treatment experiences and clinical characteristics in migraine and tension-type headache patients before the first visit to a tertiary headache center.
    Cephalalgia. 2022 May 27:3331024221104178. doi: 10.1177/03331024221104178.
    PubMed     Abstract available

  32. VERHAGEN IE, Spaink HA, van der Arend BW, van Casteren DS, et al
    Validation of diagnostic ICHD-3 criteria for menstrual migraine.
    Cephalalgia. 2022 May 6:3331024221099031. doi: 10.1177/03331024221099031.
    PubMed     Abstract available

  33. HELFENSTEIN C, Strupf M, Stefke A, Fraunberger B, et al
    Cyclic changes of sensory parameters in migraine patients.
    Cephalalgia. 2022 May 6:3331024221097932. doi: 10.1177/03331024221097932.
    PubMed     Abstract available

  34. NOSER AE, Klages KL, Gamwell KL, Brammer CN, et al
    A systematic evaluation of primary headache management apps leveraging behavior change techniques.
    Cephalalgia. 2022;42:510-523.
    PubMed     Abstract available

  35. CHIANG CC, Shahid AH, Harriott AM, Tietjen GE, et al
    Evaluation and treatment of headache associated with moyamoya disease - a narrative review.
    Cephalalgia. 2022;42:542-552.
    PubMed     Abstract available

    April 2022
  36. GEPPETTI P, De Cesaris F, Benemei S, Cortelli P, et al
    Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study.
    Cephalalgia. 2022 Apr 26:3331024221093712. doi: 10.1177/03331024221093712.
    PubMed     Abstract available

  37. MOHAMAD SAFIAI NI, Mohamad NA, Basri H, Inche Mat LN, et al
    High-frequency repetitive transcranial magnetic stimulation at dorsolateral prefrontal cortex for migraine prevention: A systematic review and meta-analysis.
    Cephalalgia. 2022 Apr 17:3331024221092423. doi: 10.1177/03331024221092423.
    PubMed     Abstract available

  38. PAN LH, Wang YF, Ling YH, Lai KL, et al
    Pain sensitivities predict prophylactic treatment outcomes of flunarizine in chronic migraine patients: A prospective study.
    Cephalalgia. 2022 Apr 11:3331024221080572. doi: 10.1177/03331024221080572.
    PubMed     Abstract available

  39. NIKOLOVA S, Schwedt TJ, Li J, Wu T, et al
    T2* reduction in patients with acute post-traumatic headache.
    Cephalalgia. 2022;42.
    PubMed     Abstract available

    March 2022
  40. DI ANTONIO S, Arendt-Nielsen L, Ponzano M, Bovis F, et al
    Cervical musculoskeletal impairments in the 4 phases of the migraine cycle in episodic migraine patients.
    Cephalalgia. 2022 Mar 25:3331024221082506. doi: 10.1177/03331024221082506.
    PubMed     Abstract available

  41. PETRUSIC I, Jovanovic V, Kovic V, Savic AM, et al
    P3 latency as a biomarker for the complexity of migraine with aura: Event-related potential study.
    Cephalalgia. 2022 Mar 25:3331024221090204. doi: 10.1177/03331024221090204.
    PubMed     Abstract available

  42. BUTT JH, S Eddelien H, Kruuse C
    The headache and aura-inducing effects of sildenafil in patients with migraine with aura.
    Cephalalgia. 2022 Mar 25:3331024221088998. doi: 10.1177/03331024221088998.
    PubMed     Abstract available

  43. MCALLISTER P, Kudrow D, Cady R, Hirman J, et al
    Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine.
    Cephalalgia. 2022 Mar 25:3331024221089567. doi: 10.1177/03331024221089567.
    PubMed     Abstract available

  44. FERNANDEZ-DE-LAS-PENAS C, Navarro-Santana MJ, Curiel-Montero F, Plaza-Manzano G, et al
    Localized and widespread pressure pain hypersensitivity in patients with episodic or chronic migraine: A systematic review and meta-analysis.
    Cephalalgia. 2022 Mar 25:3331024221084217. doi: 10.1177/03331024221084217.
    PubMed     Abstract available

  45. DIENER HC, McAllister P, Jurgens TP, Kessler Y, et al
    Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
    Cephalalgia. 2022 Mar 25:3331024221076485. doi: 10.1177/03331024221076485.
    PubMed     Abstract available

  46. ASHINA M, McAllister P, Cady R, Hirman J, et al
    Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.
    Cephalalgia. 2022 Mar 18:3331024221077646. doi: 10.1177/03331024221077646.
    PubMed     Abstract available

  47. WANG YF, Liao YC, Tzeng YS, Chen SP, et al
    Mutation screening and association analysis of NOTCH3 p.R544C in patients with migraine with or without aura.
    Cephalalgia. 2022 Mar 18:3331024221080891. doi: 10.1177/03331024221080891.
    PubMed     Abstract available

  48. KWON S, Gil YE, Lee MJ
    Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients.
    Cephalalgia. 2022 Mar 18:3331024221076481. doi: 10.1177/03331024221076481.
    PubMed     Abstract available

  49. MILOSEVIC N, Trajkovic JZ, Mijajlovic M, Milosevic J, et al
    The burden and health care use of patients with migraine and tension-type headache in post-conflict area of Serbia.
    Cephalalgia. 2022 Mar 18:3331024221082061. doi: 10.1177/03331024221082061.
    PubMed     Abstract available

  50. HIRTZ C, Adam G, Raposo N, Fabre N, et al
    Diagnostic utility of T2*-weighted GRE in migraine with aura attack. The cortical veins sign.
    Cephalalgia. 2022 Mar 18:3331024221076484. doi: 10.1177/03331024221076484.
    PubMed     Abstract available

  51. THURAIAIYAH J, Kokoti L, Al-Karagholi MA, Ashina M, et al
    Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies.
    Cephalalgia. 2022 Mar 18:3331024221077665. doi: 10.1177/03331024221077665.
    PubMed     Abstract available

  52. CHOWDHURY D, Mundra A, Datta D, Duggal A, et al
    Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial.
    Cephalalgia. 2022 Mar 8:3331024221082077. doi: 10.1177/03331024221082077.
    PubMed     Abstract available

  53. VAZ JM, Alves BM, Duarte DB, Marques LA, et al
    Quality appraisal of existing guidelines for the management of headache disorders by the AGREE II's method.
    Cephalalgia. 2022;42:239-249.
    PubMed     Abstract available

    February 2022
  54. MATAMALA-GOMEZ M, Bottiroli S, Sances G, Allena M, et al
    Facial expressions modulate pain perception in patients with chronic migraine.
    Cephalalgia. 2022 Feb 15:3331024221075081. doi: 10.1177/03331024221075081.
    PubMed     Abstract available

  55. SEBASTIANELLI G, Abagnale C, Casillo F, Cioffi E, et al
    Bimodal sensory integration in migraine: A study of the effect of visual stimulation on somatosensory evoked cortical responses.
    Cephalalgia. 2022 Feb 15:3331024221075073. doi: 10.1177/03331024221075073.
    PubMed     Abstract available

  56. KIM J, Park CG, Chu MK
    Interictal plasma endothelin-1 levels do not change in individuals with episodic and chronic migraine.
    Cephalalgia. 2022 Feb 15:3331024221075616. doi: 10.1177/03331024221075616.
    PubMed     Abstract available

  57. STOVNER LJ, Hagen K, Tronvik E, Bruvik Gravdahl G, et al
    FollowTheSutures: Piloting a new way to administer onabotulinumtoxinA for chronic migraine.
    Cephalalgia. 2022 Feb 15:3331024211067775. doi: 10.1177/03331024211067775.
    PubMed     Abstract available

  58. NUOTTAMO ME, Happola P, Artto V, Hautakangas H, et al
    NCOR2 is a novel candidate gene for migraine-epilepsy phenotype.
    Cephalalgia. 2022 Feb 15:3331024211068065. doi: 10.1177/03331024211068065.
    PubMed     Abstract available

  59. AL-KHAZALI HM, Younis S, Al-Sayegh Z, Ashina S, et al
    Prevalence of neck pain in migraine: A systematic review and meta-analysis.
    Cephalalgia. 2022 Feb 15:3331024211068073. doi: 10.1177/03331024211068073.
    PubMed     Abstract available

  60. MESSLINGER K, Neuhuber W, May A
    Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19.
    Cephalalgia. 2022;42:176-180.
    PubMed     Abstract available

    January 2022
  61. NAJIB U, Smith T, Hindiyeh N, Saper J, et al
    Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial.
    Cephalalgia. 2022 Jan 9:3331024211068813. doi: 10.1177/03331024211068813.
    PubMed     Abstract available

  62. MCGINLEY JS, Houts CR, Wirth RJ, Lipton RB, et al
    Measuring headache day severity using multiple features in daily diary designs.
    Cephalalgia. 2022;42:53-62.
    PubMed     Abstract available

    December 2021
  63. ELIZAGARAY-GARCIA I, Carvalho GF, Szikszay TM, Adamczyk WM, et al
    Psychophysical testing in chronic migraine and chronic tension type headache: An observational study.
    Cephalalgia. 2021 Dec 7:3331024211060315. doi: 10.1177/03331024211060315.
    PubMed     Abstract available

  64. OLIVEIRA AB, Mercante JPP, Peres MFP, Molina MDCB, et al
    Physical inactivity and headache disorders: Cross-sectional analysis in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
    Cephalalgia. 2021;41:1467-1485.
    PubMed     Abstract available

  65. NERI I, Menichini D, Monari F, Bascio LS, et al
    Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
    Cephalalgia. 2021;41:1492-1498.
    PubMed     Abstract available

    November 2021
  66. CHRISTENSEN SL, Rasmussen RH, Cour S, Ernstsen C, et al
    Smooth muscle ATP-sensitive potassium channels mediate migraine-relevant hypersensitivity in mouse models.
    Cephalalgia. 2021 Nov 24:3331024211053570. doi: 10.1177/03331024211053570.
    PubMed     Abstract available

  67. MALEKIAN N, Bastani PB, Oveisgharan S, Nabaei G, et al
    Preventive effect of greater occipital nerve block on patients with episodic migraine: A randomized double-blind placebo-controlled clinical trial.
    Cephalalgia. 2021 Nov 17:3331024211058182. doi: 10.1177/03331024211058182.
    PubMed     Abstract available

  68. CHHABRA N, Chiang CC, Di Nome MA, Houghton O, et al
    Migrainous infarction of the eye: Two cases of monocular ischemic complications associated with retinal migraine.
    Cephalalgia. 2021 Nov 17:3331024211056286. doi: 10.1177/03331024211056286.
    PubMed     Abstract available

  69. NEVERDAHL JP, Uglem M, Matre D, Hansen JO, et al
    Pain thresholds and suprathreshold pain after sleep restriction in migraine - A blinded crossover study.
    Cephalalgia. 2021 Nov 17:3331024211056565. doi: 10.1177/03331024211056565.
    PubMed     Abstract available

  70. TOGHA M, Martami F, Jafari E, Ariyanfar S, et al
    The prevalence and characteristics of visceral autonomic symptoms among migraineurs: A population-based study.
    Cephalalgia. 2021 Nov 17:3331024211056849. doi: 10.1177/03331024211056849.
    PubMed     Abstract available

  71. REUTER U, Ehrlich M, Gendolla A, Heinze A, et al
    Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.
    Cephalalgia. 2021 Nov 7:3331024211053571. doi: 10.1177/03331024211053571.
    PubMed     Abstract available

  72. PARAKRAMAWEERA R, Evans RW, Schor LI, Pearson SM, et al
    A brief diagnostic screen for cluster headache: Creation and initial validation of the Erwin Test for Cluster Headache.
    Cephalalgia. 2021;41:1298-1309.
    PubMed     Abstract available

    October 2021
  73. HAPPOLA P, Gormley P, Nuottamo ME, Artto V, et al
    Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families.
    Cephalalgia. 2021 Oct 14:3331024211045651. doi: 10.1177/03331024211045651.
    PubMed     Abstract available

  74. OVEREEM LH, Peikert A, Hofacker MD, Kamm K, et al
    Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
    Cephalalgia. 2021 Oct 13:3331024211048765. doi: 10.1177/03331024211048765.
    PubMed     Abstract available

  75. MESSINA R, Rocca MA, Valsasina P, Misci P, et al
    Clinical correlates of hypothalamic functional changes in migraine patients.
    Cephalalgia. 2021 Oct 13:3331024211046618. doi: 10.1177/03331024211046618.
    PubMed     Abstract available

  76. KANG L, Tang W, Zhang Y, Zhang M, et al
    The gut microbiome modulates nitroglycerin-induced migraine-related hyperalgesia in mice.
    Cephalalgia. 2021 Oct 13:3331024211050036. doi: 10.1177/03331024211050036.
    PubMed     Abstract available

  77. REUTER U, Krege JH, Lombard L, Gomez Valderas E, et al
    Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
    Cephalalgia. 2021 Oct 13:3331024211048507. doi: 10.1177/03331024211048507.
    PubMed     Abstract available

  78. ALPUENTE A, Gallardo VJ, Asskour L, Caronna E, et al
    Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks.
    Cephalalgia. 2021 Oct 4:3331024211040467. doi: 10.1177/03331024211040467.
    PubMed     Abstract available

  79. FRANK F, Ulmer H, Sidoroff V, Broessner G, et al
    CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis.
    Cephalalgia. 2021;41.
    PubMed     Abstract available

  80. TANHA HM, Martin NG, Whitfield JB, Nyholt DR, et al
    Association and genetic overlap between clinical chemistry tests and migraine.
    Cephalalgia. 2021;41.
    PubMed     Abstract available

  81. GONZALEZ-QUINTANILLA V, Perez-Pereda S, Gonzalez-Suarez A, Madera J, et al
    Restless legs-like syndrome as an emergent adverse event of CGRP monoclonal antibodies: A report of two cases.
    Cephalalgia. 2021;41.
    PubMed     Abstract available

  82. VAN CASTEREN DS, Verhagen IE, de Boer I, de Vries Lentsch S, et al
    E-diary use in clinical headache practice: A prospective observational study.
    Cephalalgia. 2021;41.
    PubMed     Abstract available

    September 2021
  83. LOBO R, Wang M, Lobo S, Bahra A, et al
    Time to retire 'New daily persistent headache': Mode of onset of chronic migraine and tension-type headache.
    Cephalalgia. 2021 Sep 27:3331024211044440. doi: 10.1177/03331024211044440.
    PubMed     Abstract available

  84. KIM S, Lee SB, Hong YJ, Kim Y, et al
    The influence of endogenous and exogenous hormonal factors on migraine in spontaneous postmenopausal women: A nationwide population-based study in South Korea.
    Cephalalgia. 2021 Sep 27:3331024211044441. doi: 10.1177/03331024211044441.
    PubMed     Abstract available

  85. CHOWDHURY D, Bansal L, Duggal A, Datta D, et al
    TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine.
    Cephalalgia. 2021 Sep 27:3331024211047454. doi: 10.1177/03331024211047454.
    PubMed     Abstract available

  86. RAFFAELLI B, Terhart M, Overeem LH, Mecklenburg J, et al
    Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study.
    Cephalalgia. 2021 Sep 27:3331024211046617. doi: 10.1177/03331024211046617.
    PubMed     Abstract available

  87. INAN LE, Inan N
    Greater occipital nerve block in migraine may have a place in migraine treatment.
    Cephalalgia. 2021 Sep 23:3331024211045644. doi: 10.1177/03331024211045644.

  88. BOTTIROLI S, Galli F, Ballante E, Pazzi S, et al
    Validity of the Severity of Dependence Scale for detecting dependence behaviours in chronic migraine with medication overuse.
    Cephalalgia. 2021 Sep 20:3331024211039817. doi: 10.1177/03331024211039817.
    PubMed     Abstract available

  89. PUTANANICKAL N, Gross EC, Orsini AL, Schmidt S, et al
    Efficacy and safety of exogenous beta-hydroxybutyrate for preventive treatment in episodic migraine: A single-centred, randomised, placebo-controlled, double-blind crossover trial.
    Cephalalgia. 2021 Sep 20:3331024211043792. doi: 10.1177/03331024211043792.
    PubMed     Abstract available

  90. CORRIGENDUM to 'Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis'.
    Cephalalgia. 2021 Sep 14:3331024211042798. doi: 10.1177/03331024211042798.

  91. SCHWEDT TJ, Lipton RB, Ailani J, Silberstein SD, et al
    Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
    Cephalalgia. 2021 Sep 14:3331024211042385. doi: 10.1177/03331024211042385.
    PubMed     Abstract available

  92. IKEGAMI D, Navratilova E, Yue X, Moutal A, et al
    A prolactin-dependent sexually dimorphic mechanism of migraine chronification.
    Cephalalgia. 2021 Sep 12:3331024211039813. doi: 10.1177/03331024211039813.
    PubMed     Abstract available

    August 2021
  93. LIPTON RB, Dodick DW, Kudrow D, Reuter U, et al
    Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
    Cephalalgia. 2021 Aug 18:3331024211028966. doi: 10.1177/03331024211028966.
    PubMed     Abstract available

  94. TFELT-HANSEN P, Jorgensen K, Diener HC
    Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks.
    Cephalalgia. 2021 Aug 18:3331024211029939. doi: 10.1177/03331024211029939.
    PubMed     Abstract available

  95. CHRISTENSEN SL, Rasmussen RH, Ernstsen C, La Cour S, et al
    CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine.
    Cephalalgia. 2021 Aug 18:3331024211038884. doi: 10.1177/03331024211038884.
    PubMed     Abstract available

  96. PENG KP, Schellong M, May A
    Aura in trigeminal autonomic cephalalgia is probably mediated by comorbid migraine with aura.
    Cephalalgia. 2021 Aug 18:3331024211030499. doi: 10.1177/03331024211030499.
    PubMed     Abstract available

  97. GIL-GOUVEIA R, Oliveira AG
    Are PROMs passing the message? A reflection with real-life migraine patients.
    Cephalalgia. 2021 Aug 18:3331024211034509. doi: 10.1177/03331024211034509.
    PubMed     Abstract available

  98. ROZEN TD, Bhatt AA
    Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention.
    Cephalalgia. 2021 Aug 18:3331024211037277. doi: 10.1177/03331024211037277.
    PubMed     Abstract available

  99. BEIER D, Callesen HE, Carlsen LN, Birkefoss K, et al
    Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education in migraine treatment. A systematic review and meta-analysis.
    Cephalalgia. 2021 Aug 18:3331024211034489. doi: 10.1177/03331024211034489.
    PubMed     Abstract available

  100. MARTINELLI D, Arceri S, De Icco R, Allena M, et al
    BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm.
    Cephalalgia. 2021 Aug 18:3331024211034508. doi: 10.1177/03331024211034508.
    PubMed     Abstract available

  101. MCGINLEY JS, Savord A, Houts CR, Wirth RJ, et al
    What do people want to know about "Growing Up with Migraine"? Results of a preference survey of people with lived experience to guide future research.
    Cephalalgia. 2021 Aug 18:3331024211038526. doi: 10.1177/03331024211038526.
    PubMed     Abstract available

  102. AL-HASSANY L, Vries T, Carpay JA, MaassenVanDenBrink A, et al
    Could erectile dysfunction be a side effect of CGRP inhibition? A case report.
    Cephalalgia. 2021 Aug 18:3331024211037304. doi: 10.1177/03331024211037304.
    PubMed     Abstract available

  103. REIDY BL, Peugh J, Hershey AD, Coffey CS, et al
    Trajectory of treatment response in the child and adolescent migraine prevention (CHAMP) study: A randomized clinical trial.
    Cephalalgia. 2021 Aug 17:3331024211033551. doi: 10.1177/03331024211033551.
    PubMed     Abstract available

  104. MILOSEVIC N, Trajkovic JZ, Mijajlovic M, Milosevic J, et al
    The first prevalence study of primary headaches in adults in a post-conflict area of Serbia.
    Cephalalgia. 2021;41:959-967.
    PubMed     Abstract available

  105. HUTCHINSON S, Silberstein SD, Blumenfeld AM, Lipton RB, et al
    Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
    Cephalalgia. 2021;41:979-990.
    PubMed     Abstract available

  106. MEHTA DG, Garza I, Robertson CE
    Two hundred and forty-eight cases of visual snow: A review of potential inciting events and contributing comorbidities.
    Cephalalgia. 2021;41:1015-1026.
    PubMed     Abstract available

    July 2021
    Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review.
    Cephalalgia. 2021 Jul 18:3331024211028959. doi: 10.1177/03331024211028959.
    PubMed     Abstract available

  108. ROXAS A JR, Quiles LE, Wang SJ
    Delivery of care for migraine in the Asian Oceanian region: A cross-sectional study.
    Cephalalgia. 2021 Jul 18:3331024211024153. doi: 10.1177/03331024211024153.
    PubMed     Abstract available

  109. CERAMI C, Crespi C, Bottiroli S, Santi GC, et al
    High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients.
    Cephalalgia. 2021 Jul 13:3331024211027568. doi: 10.1177/03331024211027568.
    PubMed     Abstract available

  110. AKERMAN S, Salvemini D, Romero-Reyes M
    Targeting reactive nitroxidative species in preclinical models of migraine.
    Cephalalgia. 2021 Jul 13:3331024211017884. doi: 10.1177/03331024211017884.
    PubMed     Abstract available

  111. DAVIDSSON OB, Olofsson IA, Kogelman LJ, Andersen MA, et al
    Twenty-five years of triptans - a nationwide population study.
    Cephalalgia. 2021;41:894-904.
    PubMed     Abstract available

    June 2021
  112. MACKENZIE KD, Stratton JR
    Response to letter to the Editor: Assessing migraine therapeutics.
    Cephalalgia. 2021 Jun 30:3331024211021563. doi: 10.1177/03331024211021563.

  113. XU C, Bussiere J
    Assessing migraine therapeutics.
    Cephalalgia. 2021 Jun 30:3331024211021569. doi: 10.1177/03331024211021569.

  114. WANG SJ, Roxas AA Jr, Saravia B, Kim BK, et al
    Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.
    Cephalalgia. 2021 Jun 25:3331024211024160. doi: 10.1177/03331024211024160.
    PubMed     Abstract available

  115. GERSTL L, Tadych N, Heinen F, Kainz C, et al
    Migraine and the development of additional psychiatric and pain disorders in the transition from adolescence to adulthood.
    Cephalalgia. 2021 Jun 23:3331024211021792. doi: 10.1177/03331024211021792.
    PubMed     Abstract available

  116. BENBOW T, Cairns BE
    Dysregulation of the peripheral glutamatergic system: A key player in migraine pathogenesis?
    Cephalalgia. 2021 Jun 20:3331024211017882. doi: 10.1177/03331024211017882.
    PubMed     Abstract available

  117. FRESE A, Summ O, Evers S
    CGRP release in an experimental human trigeminal pain model.
    Cephalalgia. 2021 Jun 20:3331024211017250. doi: 10.1177/03331024211017250.
    PubMed     Abstract available

  118. LENGYEL M, Hajdu D, Dobolyi A, Rosta J, et al
    TRESK background potassium channel modifies the TRPV1-mediated nociceptor excitability in sensory neurons.
    Cephalalgia. 2021;41:827-838.
    PubMed     Abstract available

  119. CONSTANTINIDIS TS, Arvaniti C, Fakas N, Rudolf J, et al
    A population-based survey for disabling headaches in Greece: Prevalence, burden and treatment preferences.
    Cephalalgia. 2021;41:810-820.
    PubMed     Abstract available

    May 2021
  120. COHEN-BARAK O, Radivojevic A, Jones A, Fiedler-Kelly J, et al
    Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach.
    Cephalalgia. 2021 May 17:3331024211007789. doi: 10.1177/03331024211007789.
    PubMed     Abstract available

  121. GANTENBEIN AR, Agosti R, Gobbi C, Flugel D, et al
    Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study.
    Cephalalgia. 2021 May 17:3331024211014616. doi: 10.1177/03331024211014616.
    PubMed     Abstract available

  122. TASSORELLI C, Diener HC, Silberstein SD, Dodick DW, et al
    Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine.
    Cephalalgia. 2021 May 14:3331024211010413. doi: 10.1177/03331024211010413.
    PubMed     Abstract available

  123. WILKINS AJ, Haigh SM, Mahroo OA, Plant GT, et al
    Photophobia in migraine: A symptom cluster?
    Cephalalgia. 2021 May 14:3331024211014633. doi: 10.1177/03331024211014633.
    PubMed     Abstract available

  124. PAZDERA L, Cohen JM, Ning X, Campos VR, et al
    Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.
    Cephalalgia. 2021 May 14:3331024211008401. doi: 10.1177/03331024211008401.
    PubMed     Abstract available

  125. LIPTON RB, Burstein R, Buse DC, Dodick DW, et al
    Efficacy of erenumab in chronic migraine patients with and without ictal allodynia.
    Cephalalgia. 2021 May 13:3331024211010305. doi: 10.1177/03331024211010305.
    PubMed     Abstract available

  126. CORRIGENDUM to 'Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN'.
    Cephalalgia. 2021 May 5:3331024211015848. doi: 10.1177/03331024211015848.

  127. DIENER HC, Ashina M, Ritter S, Paiva Da Silva Lima G, et al
    Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.
    Cephalalgia. 2021 May 3:3331024211010308. doi: 10.1177/03331024211010308.
    PubMed     Abstract available

  128. YOUNG AS, Nham B, Bradshaw AP, Calic Z, et al
    Clinical, oculographic, and vestibular test characteristics of vestibular migraine.
    Cephalalgia. 2021 May 2:3331024211006042. doi: 10.1177/03331024211006042.
    PubMed     Abstract available

  129. SCHWEDT TJ, Sahai-Srivastava S, Murinova N, Birlea M, et al
    Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trial.
    Cephalalgia. 2021 May 2:3331024211006903. doi: 10.1177/03331024211006903.
    PubMed     Abstract available

    April 2021
  130. CHONG CD, Berisha V, Ross K, Kahn M, et al
    Distinguishing persistent post-traumatic headache from migraine: Classification based on clinical symptoms and brain structural MRI data.
    Cephalalgia. 2021 Apr 29:333102421991819. doi: 10.1177/0333102421991819.
    PubMed     Abstract available

  131. POHL H, Benemei S, Garcia-Azorin D, Dixon J, et al
    Time lost due to an attack - a novel patient-reported outcome measure for acute migraine treatments.
    Cephalalgia. 2021 Apr 19:3331024211006048. doi: 10.1177/03331024211006048.
    PubMed     Abstract available

  132. RAOOF N, Hoffmann J
    Diagnosis and treatment of idiopathic intracranial hypertension.
    Cephalalgia. 2021;41:472-478.
    PubMed     Abstract available

  133. CERIANI CE, Silberstein SD
    Headache and rhinosinusitis: A review.
    Cephalalgia. 2021;41:453-463.
    PubMed     Abstract available

    March 2021
  134. ROTHROCK JF, Diener HC
    Headache secondary to cerebrovascular disease.
    Cephalalgia. 2021 Mar 18:333102421999045. doi: 10.1177/0333102421999045.
    PubMed     Abstract available

  135. ZHANG Y, Zhao X, Wang Y, Dong Z, et al
    Prevalence and characteristics of cough headache in a Chinese respiratory clinic.
    Cephalalgia. 2021;41:366-374.
    PubMed     Abstract available

  136. VINOGRADOVA LV, Suleymanova EM, Medvedeva TM
    Transient loss of interhemispheric functional connectivity following unilateral cortical spreading depression in awake rats.
    Cephalalgia. 2021;41:353-365.
    PubMed     Abstract available

    February 2021
  137. SHAH R, Assis F, Narasimhan B, Khachadourian V, et al
    Trans-nasal high-flow dehumidified air in acute migraine headaches: A randomized controlled trial.
    Cephalalgia. 2021 Feb 25:333102421997766. doi: 10.1177/0333102421997766.
    PubMed     Abstract available

  138. WANG X, Yin Z, Lian Y, Xu Y, et al
    Premonitory symptoms in migraine from China: A multi-clinic study of 4821 patients.
    Cephalalgia. 2021 Feb 25:333102421997850. doi: 10.1177/0333102421997850.
    PubMed     Abstract available

  139. BHAKTA M, Vuong T, Taura T, Wilson DS, et al
    Migraine therapeutics differentially modulate the CGRP pathway.
    Cephalalgia. 2021 Feb 24:333102420983282. doi: 10.1177/0333102420983282.
    PubMed     Abstract available

  140. SOLLMANN N, Schandelmaier P, Weidlich D, Borner C, et al
    Patients with episodic migraine show increased T2 values of the trapezius muscles - an investigation by quantitative high-resolution magnetic resonance imaging.
    Cephalalgia. 2021 Feb 20:333102421996374. doi: 10.1177/0333102421996374.
    PubMed     Abstract available

  141. SOUTHWELL J, Afridi SK
    The burden of migraine on acute and emergency services in a London teaching hospital.
    Cephalalgia. 2021 Feb 18:333102420981734. doi: 10.1177/0333102420981734.
    PubMed     Abstract available

  142. DE TOMMASO M, Delussi M, Gentile E, Ricci K, et al
    Effect of single dose Erenumab on cortical responses evoked by cutaneous a-delta fibers: A pilot study in migraine patients.
    Cephalalgia. 2021 Feb 16:333102421996345. doi: 10.1177/0333102421996345.
    PubMed     Abstract available

  143. DRELLIA K, Kokoti L, Deligianni CI, Papadopoulos D, et al
    Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.
    Cephalalgia. 2021 Feb 10:333102421989601. doi: 10.1177/0333102421989601.
    PubMed     Abstract available

  144. WIENHOLTZ NKF, Christensen CE, Zhang DG, Coskun H, et al
    Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial.
    Cephalalgia. 2021 Feb 10:333102420975395. doi: 10.1177/0333102420975395.
    PubMed     Abstract available

  145. TCHIVILEVA IE, Ohrbach R, Fillingim RB, Lim PF, et al
    Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial.
    Cephalalgia. 2021 Feb 9:333102421989268. doi: 10.1177/0333102421989268.
    PubMed     Abstract available

  146. ASHINA M, Reuter U, Smith T, Krikke-Workel J, et al
    Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study.
    Cephalalgia. 2021 Feb 4:333102421989232. doi: 10.1177/0333102421989232.
    PubMed     Abstract available

  147. LISICKI M, Figuerola ML, Bonamico L, Lew D, et al
    The prevalence of migraine in Argentina: A reappraisal.
    Cephalalgia. 2021 Feb 1:333102421989262. doi: 10.1177/0333102421989262.
    PubMed     Abstract available

  148. CHO S, Cho SJ, Lee MJ, Park JW, et al
    Clinical characteristics of pre-attack symptoms in cluster headache: A large series of Korean patients.
    Cephalalgia. 2021;41:227-236.
    PubMed     Abstract available

    January 2021
  149. DIENER HC, Ashina M, Durand-Zaleski I, Kurth T, et al
    Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society.
    Cephalalgia. 2021 Jan 20:333102421989247. doi: 10.1177/0333102421989247.
    PubMed     Abstract available

  150. CATARCI T
    Occipital ischaemic stroke after visual snow phenomenon - a case report.
    Cephalalgia. 2021 Jan 12:333102420985444. doi: 10.1177/0333102420985444.
    PubMed     Abstract available

  151. VERHAGEN IE, van Casteren DS, Lentsch SV, Terwindt GM, et al
    Effect of lockdown during COVID-19 on migraine: A longitudinal cohort study.
    Cephalalgia. 2021 Jan 11:333102420981739. doi: 10.1177/0333102420981739.
    PubMed     Abstract available

  152. KARSAN N, Perez-Rodriguez A, Nagaraj K, Bose PR, et al
    The migraine postdrome: Spontaneous and triggered phenotypes.
    Cephalalgia. 2021 Jan 10:333102420975401. doi: 10.1177/0333102420975401.
    PubMed     Abstract available

  153. MELO-CARRILLO A, Strassman AM, Schain AJ, Adams AM, et al
    Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons.
    Cephalalgia. 2021;41:17-32.
    PubMed     Abstract available

  154. LEHMAN LL, Bruccoleri R, Danehy A, Swanson J, et al
    Adverse effects of erenumab on cerebral proliferative angiopathy: A case report.
    Cephalalgia. 2021;41:122-126.
    PubMed     Abstract available

    December 2020
  155. ILJAZI A, Ashina H, Zhuang ZA, Lopez Lopez C, et al
    Hypersensitivity to calcitonin gene-related peptide in chronic migraine.
    Cephalalgia. 2020 Dec 15:333102420981666. doi: 10.1177/0333102420981666.
    PubMed     Abstract available

  156. BEGASSE DE DHAEM O, Gharedaghi MH, Bain P, Hettie G, et al
    Identification of work accommodations and interventions associated with work productivity in adults with migraine: A scoping review.
    Cephalalgia. 2020 Dec 10:333102420977852. doi: 10.1177/0333102420977852.
    PubMed     Abstract available

  157. STRANG-KARLSSON S, Alenius S, Nasanen-Gilmore P, Nurhonen M, et al
    Migraine in children and adults born preterm: A nationwide register linkage study.
    Cephalalgia. 2020 Dec 9:333102420978357. doi: 10.1177/0333102420978357.
    PubMed     Abstract available

  158. POZO-ROSICH P, Coppola G, Pascual J, Schwedt TJ, et al
    How does the brain change in chronic migraine? Developing disease biomarkers.
    Cephalalgia. 2020 Dec 8:333102420974359. doi: 10.1177/0333102420974359.
    PubMed     Abstract available

  159. SCHRAMM S, Tenhagen I, Schmidt B, Holle-Lee D, et al
    Prevalence and risk factors of migraine and non-migraine headache in older people - results of the Heinz Nixdorf Recall study.
    Cephalalgia. 2020 Dec 3:333102420977183. doi: 10.1177/0333102420977183.
    PubMed     Abstract available

  160. IRIMIA P, Martinez-Valbuena I, Minguez-Olaondo A, Dominguez-Vivero C, et al
    Interictal amylin levels in chronic migraine patients: A case-control study.
    Cephalalgia. 2020 Dec 3:333102420977106. doi: 10.1177/0333102420977106.
    PubMed     Abstract available

  161. LIPTON RB, Tepper SJ, Silberstein SD, Kudrow D, et al
    Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
    Cephalalgia. 2020 Dec 3:333102420973994. doi: 10.1177/0333102420973994.
    PubMed     Abstract available

  162. WOOD ME, Burch RC, Hernandez-Diaz S
    Polypharmacy and comorbidities during pregnancy in a cohort of women with migraine.
    Cephalalgia. 2020 Dec 3:333102420975394. doi: 10.1177/0333102420975394.
    PubMed     Abstract available

  163. GROENKE BR, Daline IH, Nixdorf DR
    SUNCT/SUNA: Case series presenting in an orofacial pain clinic.
    Cephalalgia. 2020 Dec 3:333102420977292. doi: 10.1177/0333102420977292.
    PubMed     Abstract available

    November 2020
  164. GOADSBY PJ, Blumenfeld AM, Lipton RB, Dodick DW, et al
    Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.
    Cephalalgia. 2020 Nov 26:333102420970523. doi: 10.1177/0333102420970523.
    PubMed     Abstract available

  165. GHANIZADA H, Iljazi A, Ashina H, Do TP, et al
    Nocebo response in human models of migraine: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled, two-way crossover trials in migraine without aura and healthy volunteers.
    Cephalalgia. 2020 Nov 26:333102420970489. doi: 10.1177/0333102420970489.
    PubMed     Abstract available

  166. ASHINA M, Dolezil D, Bonner JH, Zhou L, et al
    A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.
    Cephalalgia. 2020 Nov 24:333102420970889. doi: 10.1177/0333102420970889.
    PubMed     Abstract available

  167. VAN CASTEREN DS, Verhagen IE, Onderwater GL, MaassenVanDenBrink A, et al
    Sex differences in prevalence of migraine trigger factors: A cross-sectional study.
    Cephalalgia. 2020 Nov 17:333102420974362. doi: 10.1177/0333102420974362.
    PubMed     Abstract available

  168. WANG SJ, Wu JW
    Reversion from chronic migraine to episodic migraine: A new outcome measure.
    Cephalalgia. 2020 Nov 17:333102420974004. doi: 10.1177/0333102420974004.

  169. GOLLION C, Gazagnes J, Fabry V, Barbieux-Guillot M, et al
    Atrial fibrillation and migraine with aura in young adults with ischemic stroke.
    Cephalalgia. 2020 Nov 17:333102420970880. doi: 10.1177/0333102420970880.
    PubMed     Abstract available

  170. CARVALHO GF, Luedtke K, Szikszay TM, Bevilaqua-Grossi D, et al
    Muscle endurance training of the neck triggers migraine attacks.
    Cephalalgia. 2020 Nov 17:333102420970184. doi: 10.1177/0333102420970184.
    PubMed     Abstract available

  171. LACKOVIC J, Price TJ, Dussor G
    De novo protein synthesis is necessary for priming in preclinical models of migraine.
    Cephalalgia. 2020 Nov 17:333102420970514. doi: 10.1177/0333102420970514.
    PubMed     Abstract available

  172. MASTRIA G, Mancini V, Cesare MD, Puma M, et al
    Prevalence and characteristics of Alice in Wonderland Syndrome in adult migraineurs: Perspectives from a tertiary referral headache unit.
    Cephalalgia. 2020 Nov 9:333102420968245. doi: 10.1177/0333102420968245.
    PubMed     Abstract available

  173. DODICK DW, Doty EG, Aurora SK, Ruff DD, et al
    Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine.
    Cephalalgia. 2020 Nov 3:333102420966658. doi: 10.1177/0333102420966658.
    PubMed     Abstract available

  174. KOPRUSZINSKI CM, Thornton P, Arnold J, Newton P, et al
    Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine.
    Cephalalgia. 2020 Nov 1:333102420966581. doi: 10.1177/0333102420966581.
    PubMed     Abstract available

  175. PETRUSIC I, Zidverc-Trajkovic J
    Redefining types of migraine aura.
    Cephalalgia. 2020 Nov 1:333102420970186. doi: 10.1177/0333102420970186.

  176. LEVINE A, Vanderah TW, Largent-Milnes TM
    An underrepresented majority: A systematic review utilizing allodynic criteria to examine the present scarcity of discrete animal models for episodic migraine.
    Cephalalgia. 2020 Nov 1:333102420966984. doi: 10.1177/0333102420966984.
    PubMed     Abstract available

    October 2020
  177. LINSTRA KM, Ibrahimi K, van Casteren DS, Wermer MJ, et al
    Pain perception in women with menstrually-related migraine.
    Cephalalgia. 2020 Oct 21:333102420966977. doi: 10.1177/0333102420966977.
    PubMed     Abstract available

  178. ERNSTSEN C, Christensen SL, Olesen J, Kristensen DM, et al
    No additive effect of combining sumatriptan and olcegepant in the GTN mouse model of migraine.
    Cephalalgia. 2020 Oct 15:333102420963857. doi: 10.1177/0333102420963857.
    PubMed     Abstract available

  179. RIST PM, Bernstein C, Kowalski M, Osypiuk K, et al
    Multimodal chiropractic care for migraine: A pilot randomized controlled trial.
    Cephalalgia. 2020 Oct 13:333102420963844. doi: 10.1177/0333102420963844.
    PubMed     Abstract available

  180. ZELE AJ, Dey A, Adhikari P, Feigl B, et al
    Melanopsin hypersensitivity dominates interictal photophobia in migraine.
    Cephalalgia. 2020 Oct 12:333102420963850. doi: 10.1177/0333102420963850.
    PubMed     Abstract available

  181. Migraine Trust Virtual 2020 - Author index.
    Cephalalgia. 2020;40.

  182. PERES MF, Evers S
    Using social media and search engine data in headache research.
    Cephalalgia. 2020;40:1274-1275.

    September 2020
  183. ZAGAMI AS, Shaikh S, Mahns D, Lambert GA, et al
    A potential role for two brainstem nuclei in craniovascular nociception and the triggering of migraine headache.
    Cephalalgia. 2020 Sep 29:333102420960039. doi: 10.1177/0333102420960039.
    PubMed     Abstract available

  184. KOPRUSZINSKI CM, Navratilova E, Swiokla J, Dodick DW, et al
    A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
    Cephalalgia. 2020 Sep 26:333102420959794. doi: 10.1177/0333102420959794.
    PubMed     Abstract available

  185. SMITH JH
    Have you ever experienced a headache of any kind?
    Cephalalgia. 2020;40:1132-1133.

    July 2020
  186. LIU Y, Wang M, Bian X, Qiu E, et al
    Proposed modified diagnostic criteria for recurrent painful ophthalmoplegic neuropathy: Five case reports and literature review.
    Cephalalgia. 2020 Jul 28:333102420944872. doi: 10.1177/0333102420944872.
    PubMed     Abstract available

    December 2019
  187. HVEDSTRUP J, Kolding LT, Younis S, Ashina M, et al
    Ictal neck pain investigated in the interictal state - a search for the origin of pain.
    Cephalalgia. 2019 Dec 18:333102419896369. doi: 10.1177/0333102419896369.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.